Education
About Us
Working with TipRanks
Follow Us
Harrow Health (HROW)
NASDAQ:HROW
HROW Stock Chart & Stats
$34.00
-$0.36(-1.00%)
At close: 4:00 PM EST
$34.00
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$20.85 - $54.85
Previous CloseN/A
Volume51.77K
Average Volume (3M)874.72K
Market Cap
$1.27B
Enterprise Value$1.44B
Total Cash (Recent Filing)$72.93M
Total Debt (Recent Filing)$251.98M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
May 07, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding37,229,706
10 Day Avg. Volume917,157
30 Day Avg. Volume874,724
Financial Highlights & Ratios
PEG Ratio4.91
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio41.91
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue5.31
Enterprise Value/Gross Profit7.07
Enterprise Value/Ebitda37.93
Forecast
1Y Price Target
$70.00Price Target Upside105.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.75
Revenue Forecast (FY)$369.75M
Bulls Say, Bears Say
Bulls Say
Biosimilar Commercialization OpportunityA settlement that enables an earlier U.S. launch of Opuviz, combined with the company's role as commercialization partner, increases the addressable market for the biosimilar portfolio and bolsters long-term revenue potential.
Clinical Validation And Physician AwarenessAcceptance of scientific abstracts for VEVYE and ILEVRO at a major ophthalmology meeting should increase physician awareness and support broader clinical adoption of those products.
Commercial Expansion And Salesforce GrowthManagement's plan to expand the salesforce, double covered territories, and move key products into office-based settings should broaden commercial reach and accelerate branded revenue growth.
Bears Say
Cost And Profitability PressureHigher selling and administrative expenses and acquisition-related research and development charges have weighed on reported profitability and prompted conservative analyst assumptions that could limit near-term valuation upside.
Distributor Inventory And Sales TimingElevated distributor inventory for IHEEZO is delaying the product's sales ramp and may push back expected revenue recognition from key channels.
Reimbursement HeadwindsLoss of pass-through reimbursement status is likely to reduce volumes that rely on ambulatory surgical centers and pressure utilization in those settings.
Harrow Health News
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $20.85 and its highest was $54.85 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $1.27B.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is May 07, 2026 which is in 44 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on Mar 02, 2026. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.368 by -$0.198.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is -0.35.
How many shares outstanding does Harrow Health have?
Harrow Health has 37,229,706 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of $0.17 in its last earnings report, missing expectations of $0.368. Following the earnings report the stock price went down -27.962%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.00 (105.88% Upside)
$70.00 (105.88% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 57.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.67%
12-Months-Change
Fundamentals
Return on Equity
-10.00%
Trailing 12-Months
Asset Growth
4.18%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive outlook: strong 2025 financial performance with double‑digit revenue growth, significant adjusted EBITDA expansion, healthy cash generation, multiple product-specific accelerations (BYOOVIZ, IHEEZO, TRIESENCE, VEVYE), concrete 2026 guidance with clear second‑half weighting, and promising pipeline milestones (G-MELT NDA target, IHEEZO data flow). Near‑term headwinds — Q1 seasonality/channel drawdown, ASC pass‑through loss for IHEEZO, compounding inventory issues, and planned SG&A/R&D investments — are acknowledged and largely presented as manageable or temporary in nature. Given the weight and scale of the positive operating and financial indicators relative to the near-term, addressable challenges, the overall tone is constructive and growth‑oriented.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$70.00
▲(105.88% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
21.34% Insiders
10.06% Mutual Funds
27.46% Other Institutional Investors
30.09% Public Companies and Individual Investors